Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | BRD1 | O95696 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 14/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057054 | 0.94 | LGALS8 (0.41) | HRH3BRD1BRPF1MEN1PABPC1 | |
| SCHEMBL3707570 | 0.91 | STAT3 (0.39) | STAT3KMT2ATGFBR1 | |
| SCHEMBL3057011 | 0.90 | STAT3 (0.40) | HRH3STAT3 | |
| SCHEMBL3058988 | 0.89 | STAT3 (0.49) | STAT3TGFBR1 | |
| Hydrochloric Acid SCHEMBL3056386 | 0.88 | SCN9A (0.42) | HRH3BRD1BRPF1STAT3MEN1 | |
| SCHEMBL3046226 | 0.86 | HRH3 (0.45) | HRH3STAT3 | |
| SCHEMBL3057012 | 0.85 | HRH3 (0.40) | HRH3STAT3 | |
| SCHEMBL3060850 | 0.85 | STAT3 (0.49) | STAT3 | |
| SCHEMBL3062606 | 0.85 | ALDH1A1 (0.44) | STAT3MEN1KMT2ATGFBR1 | |
| SCHEMBL3061648 | 0.84 | LGALS8 (0.39) | HRH3STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | HRH3 19/4885BRD1 348/4885BRPF1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.